BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32587095)

  • 1. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
    Swan RL; Poh LLK; Cowell IG; Austin CA
    Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Role for VCP/p97 in the Processing of Drug-Stabilized TOP2-DNA Covalent Complexes.
    Swan RL; Cowell IG; Austin CA
    Mol Pharmacol; 2021 Jul; 100(1):57-62. PubMed ID: 33941661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity.
    Sciascia N; Wu W; Zong D; Sun Y; Wong N; John S; Wangsa D; Ried T; Bunting SF; Pommier Y; Nussenzweig A
    Elife; 2020 Feb; 9():. PubMed ID: 32057297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.
    Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
    Ma Y; North BJ; Shu J
    Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
    Swan RL; Cowell IG; Austin CA
    Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.
    Alchanati I; Teicher C; Cohen G; Shemesh V; Barr HM; Nakache P; Ben-Avraham D; Idelevich A; Angel I; Livnah N; Tuvia S; Reiss Y; Taglicht D; Erez O
    PLoS One; 2009 Dec; 4(12):e8104. PubMed ID: 19956605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
    Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
    Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
    Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
    Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
    Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of topoisomerase 2 DNA-protein crosslink resolution.
    Riccio AA; Schellenberg MJ; Williams RS
    Cell Mol Life Sci; 2020 Jan; 77(1):81-91. PubMed ID: 31728578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
    Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
    DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
    Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
    Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison.
    Cowell IG; Ling EM; Swan RL; Brooks MLW; Austin CA
    Mol Pharmacol; 2019 Nov; 96(5):562-572. PubMed ID: 31515282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
    Atwal M; Lishman EL; Austin CA; Cowell IG
    Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
    Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
    Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Untangling trapped topoisomerases with tyrosyl-DNA phosphodiesterases.
    Zagnoli-Vieira G; Caldecott KW
    DNA Repair (Amst); 2020 Oct; 94():102900. PubMed ID: 32653827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner.
    Shu J; Jiang J; Wang X; Yang X; Zhao G; Cai T
    Cell Death Dis; 2024 Jan; 15(1):83. PubMed ID: 38263255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FEN1 participates in repair of the 5'-phosphotyrosyl terminus of DNA single-strand breaks.
    Kametani Y; Takahata C; Narita T; Tanaka K; Iwai S; Kuraoka I
    Carcinogenesis; 2016 Jan; 37(1):56-62. PubMed ID: 26581212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses.
    Fan JR; Peng AL; Chen HC; Lo SC; Huang TH; Li TK
    DNA Repair (Amst); 2008 Mar; 7(3):452-63. PubMed ID: 18206427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.